Sinovac Biotech (SVA) Receives Third Order For H1NI Vaccine In China
More News related to SVA
- Sinovac to Present at Piper Jaffray Health Care Conference
- Notable Analyst Rating Changes 11/19: AMD, TGT, XL, SCSS Upgraded; INTC, ASMI, HOTT, SMH/INTC/TXN/MRVL Downgraded
- Brean Murray Assumes Coverage on Sinovac Biotech (SVA) with a Buy
- Sinovac Files Shelf Registration Statement
- Sinovac Biotech (SVA) Files 10M Share Shelf
More News related to FDA
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
Sinovac Biotech Ltd. (NYSE: SVA) received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.
Under this purchase order, Sinovac is required to produce an additional 5.19 million doses of PANFLU.1 (15ug/0.5ml) for the Chinese central government. Out of today's announced PANFLU.1 order, Sinovac is required to complete delivery of 2.89 million doses to the appointed provincial and municipal governments by the end of this year and supply the remaining 2.3 million doses for the central government stockpiling.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
